Skip to main content

Tagged With "Tezepelumab"

Blog Post

Amgen Submits Biologics License Application for Tezepelumab for Severe Asthma

AAFA Community Services ·
Amgen today announced its partner AstraZeneca submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for tezepelumab, a potential first-in-class medicine in severe asthma.
×
×
×
×